Bibliographie

[1] Mandal S, Maharana PK, Kaweri L, et al. Management and prevention of corneal graft rejectionIndian. J Ophthalmol 2023;71(9):3149–59.
[2] Panda A, Vanathi M, Kumar A, et al. Corneal graft rejection. Surv Ophthalmol 2007;52(4):375–96.
[3] Hill JC, Maske R, Watson PG. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy Ophthalmology 1991;98(3):329–33.
[4] Hill JC, Maske R, Watson PG. A preliminary report. The use of a single pulse of intravenous methylprednisolone in the treatment of corneal graft rejection. Eye (Lond) 1991;5(Pt 4):420–4.
[5] Hill JC, Maske R, Watson PG. Corticosteroids in corneal graft rejection. Cornea 1994;13(5):383–8.
[6] Costa DC, de Castro RS, Kara-Jose N. Case-control study of subconjunctival triamcinolone acetonide injection vs intravenous methylprednisolone pulse in the treatment of endothelial corneal allograft rejection. Eye (Lond) 2009;23(3):708–14.
[7] Nguyen NX, Seitz B, Martus P, et al. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol 2007;144(2):318–9.
[8] Price MO, Price Jr FW, Kruse FE, et al. Randomized comparison of topical prednisolone acetate 1 % versus fluorometholone 0.1 % in the first year after Descemet membrane endothelial keratoplasty. Cornea 2014;33:880–6.
[9] Price MO, Scanameo A, Feng MT, et al. Descemet's membrane endothelial keratoplasty. Ophthalmology 2016;123(6):1232–6.
[10] Ziaei M, Manzouri B. Topical cyclosporine in corneal transplantation. Cornea 2015;34(1):110–5.
[11] Price MO, Price FW. Efficacy of topical cyclosporine 0.05 % for prevention of cornea transplant rejection episodes. Ophthalmology 2006;113:1785–90.
[12] Inoue K, Amano S, Fujita N, et al. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Jpn J Ophthalmol 2000;44:302–5.
[13] Bernardes L, Gil J, Costa E, et al. Topical tacrolimus in high-risk corneal transplant. Eur J Ophthalmol 2024;34(1):140–5.
[14] Price MO, Jordan CS, Moore G, Price FW. Graft rejection episodes after Descemet stripping with endothelial keratoplasty : part two : thestatistical analysis of probability and risk factors. Br J Ophthalmology 2009;93:391–5.
[15] Shimazaki J, Den S, Omoto M, et al. Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol 2011;152(1):33–39.e1.
[16] Joseph A, Raj D, Shanmugabathan V, et al. Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol 2007;91(1):51–5.
[17] Roshanadel D, Eslani M, Baradaran-Rafii A, et al. Current and emerging therapies for corneal neovascularization. Ocul Surf 2018;16(4):398–414.
[18] Khaireddin R, Wachtlin J, Hopfenmuller W, Hoffmann F. HLA-A, HLA-B and HLA-DR matching reduces the rate of corneal allograft rejection. Graefes Arch Clin Exp Ophthalmol 2003;241(12):1020–8.
[19] Bartels MC, Doxiadis II, Colen TP, Beekhuis WH. Long-term outcome in high-risk corneal transplantation and the influence of HLA-A and HLA-B matching. Cornea 2003;22(6):552–6.
[20] The Collaborative Corneal Transplantation Studies (CCTS) effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol 1992;110(10):1392–403.
[21] Van Essen TH, Roelen DL, Williams KA, et al. Matching for Human Leukocyte Antigens (HLA) in corneal transplantation - to do or not to do. Prog Retin Eye Res 2015;46:84–110.